Abbott Laboratories (ABT), AbbVie Inc (ABBV) & More: Did You Know That This Stock Is Half What It Had Been?

Page 2 of 2

I doubt we’ll see that happen, Abbott just got a new stent, Xience Xpedition, approved in January. Maybe the newest offering can turn things around.

Is Abbott Laboratories stock a buy?
I can see why Abbott Laboratories (NYSE:ABT) split off its drug business; the aforementioned growth in the combined stock price highlights the released value.

Of the two, though, I think AbbVie has greater potential for growth. It’s exposed to potential generic competition for its megablockbuster, Humira, but it has a nice pipeline to back it up.

Abbott Laboratories (NYSE:ABT) stock isn’t going to go anywhere until the company can get its medical device division moving back in the right direction. Unless you’re content with holding to collect the dividend, I’d recommend watching for the turnaround before investing.

The article Abbott Laboratories Stock Is Half What It Used to Be originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Page 2 of 2